GLP-1 demand has driven CDMOs to build solid-phase and liquid-phase peptide synthesis capacity at a scale considered implausible a decade ago. Neuland Laboratories warns that a single drug class should not define manufacturing strategy, because the clinical pipeline now includes peptides with…
Peptide manufacturing has moved to the center of pharmaceutical manufacturing conferences this year, and in most sessions the topic arrives attached to a single name: GLP-1 . The commercial success of weight-loss and diabetes peptides has driven contract development and manufacturing organizations CDMOs to invest in production capacity at a scale that would have seemed implausible 10 years ago.
Companies are building two kinds of peptide synthesis lines, solid-phase and liquid-phase, a two-track expansion that shows how strongly the industry expects incretin demand to keep growing. The investment wave has a dissenting note. Sajeev Emmanuel Medikonda, who leads corporate planning and strategy at Neuland Laboratories, is among those cautioning against letting one drug class define how the industry approaches peptide manufacturing.
The warning is, in essence, about the number 1. A single class, GLP-1, currently shapes equipment choices, capital plans, and conference agendas. The peptide clinical pipeline behind that class has, in the same period, grown substantially in size and breadth, and many molecules in development differ from GLP-1 in ways that matter for production. Infrastructure that suits an incretin analog may not suit a candidate with a different length, fold, or chemical conjugation.
The timing matters because the spending decisions being made now will still be depreciating when the next wave of candidates reaches manufacturing scale. If the buildout is misaligned with that wave, correction will come late and at high cost.
The concrete form of the expansion is the construction of 2 synthesis line types : solid-phase synthesis and liquid-phase synthesis . Solid-phase synthesis assembles the chain on an insoluble resin, adding amino acids one at a time and washing excess reagents away between couplings. Liquid-phase synthesis runs in solution, an older chemistry that has regained industrial attention for peptides where resin-based assembly is inefficient or costly. A manufacturer building both lines at once is placing parallel bets rather than a single one.
The two chemistries are not interchangeable, and the difference matters for what can be scaled. Solid-phase excels at routine, mid-length peptides and dominates because automation, standardized reagents, and large resin lots make it fast. Its weakness is the accumulating inefficiency of each coupling cycle and the physical behavior of the growing chain on the resin. Liquid-phase synthesis produces soluble intermediates that can be purified by extraction, crystallization, or chromatography between couplings, and it scales in ordinary stirred reactors rather than specialized solid-phase equipment. Its weakness is slower cycle times and the need to develop solubility and workup conditions for every intermediate. A plant with both line types can route a molecule to whichever chemistry fits it, but only if the supporting utilities, purification capacity, and quality systems serve both.
Liquid-phase chemistry also opens the route to fragment condensation , where short segments are assembled separately, purified, and then coupled into the full chain. The convergent strategy changes the yield arithmetic, because each segment is built and purified on its own and the final assembly uses only a few couplings. Stepwise elongation pays its efficiency tax on every residue, while fragment condensation pays it only on the junctions. That makes the approach the standard answer for long, aggregation-prone, or heavily modified sequences, and a second reason the liquid-phase line is an investment rather than a curiosity.
The scale change is visible in the manufacturing business itself. Peptide production was once a niche, small-batch service for a handful of injectable hormones and specialty drugs. Commercial demand from the weight-loss and diabetes markets has converted that niche into the basis of major capital plans. The two line types under construction are the proof of how far the business has moved.
The risk that Medikonda and others flag is structural. A buildout sized for GLP-1 is a buildout sized for a particular product profile: linear peptides of roughly 30 to 40 residues, made by solid-phase chemistry in very large batches, sold at enormous annual volumes. If that profile hardens into the industry's default, then capacity, purification trains, quality systems, and raw-material supply all become optimized for it. The caution is that the next decade's winners may not share that profile.
The molecules driving the boom fit the platform being built. Native GLP-1 is a short incretin hormone of about 30 amino acids, released from intestinal L cells after meals. It amplifies glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and signals satiety. The native hormone is degraded within minutes by the enzyme dipeptidyl peptidase-4 , so the marketed weight-loss and diabetes drugs are engineered analogs. Many carry fatty-acid acylations that bind albumin in circulation and extend half-life from minutes to days.
Chemically, these are mid-length linear peptides, squarely within the working range of solid-phase synthesis. The method, developed in the 1960s, builds the chain on a resin through repeated deprotection and coupling cycles. Each cycle runs with an excess of activated amino acid to drive the reaction near completion, and the losses compound with chain length. At 99 percent per-coupling efficiency, a 30-residue chain retains roughly 74 percent of theoretical yield before purification. That arithmetic is workable for the incretin class and punishing for longer chains.
The reasons are physical as much as chemical. As a chain grows, keeping the growing peptide solvated and accessible on the resin becomes harder. Hydrophobic sequences or sequences prone to secondary structure can aggregate, stall couplings, and generate deletion and truncation impurities that are nearly impossible to separate from the full-length product. This is why the incretin range proved commercially tractable while many longer and more difficult targets have historically stayed in the laboratory.
The fit is not accidental. The drug class and the manufacturing method reinforced each other: the molecules were designed in a size range that chemical synthesis could serve at scale, and demand justified the capital. The same reasoning that made GLP-1 a good template for solid-phase production is exactly what limits the template's reach. Length is the first constraint, but not the only one.
The production profile of the class sharpens the point. These are chronic medicines dosed in milligrams per week, a regimen that pushes annual demand well above that of most earlier peptide drugs and rewards manufacturing trains built for throughput. Downstream processing, especially high-performance liquid chromatography purification and lyophilization, was scaled to match. A different class with a different dose, route, or target population can invert each of those assumptions.
The molecules in that broader pipeline divide across structural classes that impose different manufacturing demands, and each divergence is a place where the GLP-1 template stops applying.
Cyclic peptides are synthesized as linear chains and then cyclized, often head-to-tail or through a side chain, in a dedicated step. That extra reaction changes the impurity arithmetic. Cyclization yields depend on ring size and sequence, and the linear precursor and the cyclic product can be difficult to separate when their physical properties are similar. A process developed for a linear incretin analog, where the main purification challenge is removing truncated chains, does not transfer to a molecule whose critical impurity is the failure to close the ring.
Peptide-drug conjugates pair a targeting peptide with a cytotoxic payload. They require facilities that can handle potent compounds and perform conjugation chemistry rather than simple chain assembly, which changes a plant in ways that a line diagram does not show. Containment becomes a design driver: closed processing, isolators, and cleaning validation for cytotoxic agents with low occupational exposure limits. The analytical burden also shifts, because a conjugate must be characterized not only by peptide purity but by drug-to-peptide ratio, payload position, and linker stability.
The pipeline also contains peptides that are heavily modified rather than merely longer. Backbone N-methylation, D-amino acid substitutions, and non-natural residues are used to block proteolysis and improve permeability. These modifications complicate synthesis at scale. N-alkylated amino acids couple slowly because the hindered nitrogen reacts poorly, and the specialized building blocks are expensive and sometimes single-source. A sequence assembled in a research laboratory on the hundred-milligram scale may need entirely new coupling chemistry, not simply more resin, to work in a production reactor.
Hydrocarbon-stapled peptides, designed to lock alpha-helical structure for intracellular targets, add a ring-closing metathesis step on resin and require olefin-bearing amino acids and metal catalysts. Their process chemistry is still young, and it does not resemble the incretin process in equipment, reagents, or impurity control.
The structural lesson is that the hardest chemistry in the pipeline is the reverse of the easiest chemistry at scale. The industry is building for linear, mid-length, high-volume peptides, while the molecules most likely to test the infrastructure are cyclic, conjugated, stapled, or densely modified. Liquid-phase and hybrid fragment-based synthesis are the most plausible answers for some of these, which is why the decision to build both line types matters. But a synthesis line is only one layer of a plant. The purification capacity, containment, and material flows around that line determine what can actually be manufactured.
The two-track expansion establishes real things. It shows that CDMO capital planners expect GLP-1 demand to persist. It shows that both solid-phase and liquid-phase chemistry are considered commercially bankable at large scale. And it shows that at least some manufacturers want the option to route molecules to either chemistry rather than committing to one.
It does not establish that the infrastructure will fit the rest of the pipeline. Two lines being built is a bet on current demand, not proof of future alignment. Nor does the presence of the liquid-phase line reveal how capital was divided between the two chemistries; a buildout weighted toward resin trains is a different bet from a balanced one, and the split is invisible from outside without capacity disclosures. Scale, configuration, and supporting systems still decide what a plant can make, and those choices are being optimized for a product profile that the incretin class defined.
The warning about the number 1 is therefore an argument about lock-in. Equipment, analytical methods, and supply agreements optimized for a single product profile create a default that is hard for a new molecule to escape. The cost of deviation is not just capital. A CDMO that has standardized on incretin-style processes has staff trained in those processes, analytical methods written for them, and a supply chain negotiated around them. A cyclic peptide or a conjugate arriving at that plant faces redevelopment, not just scheduling.
Regulation adds a slower-moving form of the same lock-in. A marketed peptide's manufacturing process is fixed in the chemistry, manufacturing, and controls section of its marketing authorization, and any change to the synthesis route,…
Peptides referenced: Glucagon, GLP-1.
Related reading: SG Bachem/Walporzheim U17 Squad Details for 2025-26 Season, Novadose and Pure Pharmaceuticals Lead Peptide Science Advances, Biopharma Hungry for GLP-1 Receptor Agonist Manufacturing Skills - Genetic Engineering and Biotechnology News, Samsung Biologics to Acquire PolyPeptide Group for CHF 1.46 Billion.